Miruvor
Sign up
The short answer

What studies of temelimab found

1paper on temelimab
96people in 1 study testing temelimab alone
1randomised trial, the strongest kind of study

At a glance, by condition

Long COVID: F Harms

Based on the strongest evidence, the placebo trial (low certainty): 3 findings, all F.

7 outcomes rated · see each below

How we got this

Each condition’s headline comes from its graded findings (one for each outcome and kind of study) rated with the highest certainty: the grade most of them share; a tie goes to the finding with the most people, then the most studies, then the outcome’s name. It sums up the grades below, and conditions are never combined.

What this means: Studies found temelimab made things worse for long COVID. If you’re thinking about it, talk it through with a doctor who knows ME/CFS or long COVID.

Ask about this treatment

Sign up free to read the rest of what studies found.

You’ll see the full picture: how each symptom fared, every grade with its reasons, side effects, the doses studied and all 1 paper.

The grades, in plain words

Each outcome gets a direction, a certainty and a letter read from the two. Certainty is judged with GRADE, the method Cochrane and WHO use.

  1. A
    HelpsImprovement, high certainty
    Probably helpsImprovement, moderate certainty
  2. B
    May helpImprovement, low certainty
  3. C
    Might help, very uncertainImprovement, very low certainty
    Mixed resultsStudies disagree
  4. D
    Little or no differenceStudies found little or no difference
  5. Temelimab · Long COVID is hereF
    HarmsIt made things worse

By symptom and daily life

Long COVID

Symptoms

Cognition (brain fog)1 study · 96 people received temelimab Little or no difference D
Very low certainty

Why this grade: Little or no difference, very low certainty, from randomised trials: some concerns about bias (RoB 2); one trial of 203 people found no clear difference; a small benefit can't be ruled out.

The placebo trial203 randomised · Week 24 · 54 mg/kg, once monthly / every 4 weeks for 6 IV infusions over 24 weeks

No clear difference in cognition (brain fog).

The evidence is very uncertain about the effect of temelimab on cognition (brain fog) in long COVID. Little or no difference · very low certainty D

  • Some concerns about bias (RoB 2)
  • One trial of 203 people found no clear difference; a small benefit can't be ruled out
See the 1 study
  1. Temelimab versus placebo in patients with post-COVID condition. (2026)

    People in the study
    203 randomised
    Dose
    54 mg/kg, once monthly / every 4 weeks for 6 IV infusions over 24 weeks
    Outcome
    Composite BAC score improvement relative risk brief assessment of cognition
    Effect
    no clear difference
    Risk of bias
    RoB 2: Some concerns
    Randomisation process
    Low
    Deviations from intended interventions
    Low
    Missing outcome data
    Low
    Measurement of the outcome
    Low
    Selection of the reported result
    Some concerns
Fatigue1 study · 96 people received temelimab Little or no difference D
Very low certainty

Why this grade: Little or no difference, very low certainty, from randomised trials: some concerns about bias (RoB 2); one trial of 203 people found no clear difference; a small benefit can't be ruled out.

The placebo trial203 randomised · Week 24 · 54 mg/kg, once monthly / every 4 weeks for 6 IV infusions over 24 weeks

No clear difference in fatigue.

The evidence is very uncertain about the effect of temelimab on fatigue in long COVID. Little or no difference · very low certainty D

  • Some concerns about bias (RoB 2)
  • One trial of 203 people found no clear difference; a small benefit can't be ruled out
See the 1 study
  1. Temelimab versus placebo in patients with post-COVID condition. (2026)

    People in the study
    203 randomised
    Dose
    54 mg/kg, once monthly / every 4 weeks for 6 IV infusions over 24 weeks
    Outcome
    PROMIS Fatigue SF 7a score patient-reported outcomes measurement information system fatigue short form 7a
    Effect
    no clear difference
    Risk of bias
    RoB 2: Some concerns
    Randomisation process
    Low
    Deviations from intended interventions
    Low
    Missing outcome data
    Some concerns
    Measurement of the outcome
    Low
    Selection of the reported result
    Some concerns
Anxiety1 study · 96 people received temelimab Worse F
Low certainty

Why this grade: Worse, low certainty, from randomised trials: some concerns about bias (RoB 2); few people (203 in all).

The placebo trial203 randomised · Week 24 · 54 mg/kg, once monthly / every 4 weeks for 6 IV infusions over 24 weeks

Anxiety was worse with temelimab.

Temelimab may worsen anxiety in long COVID. Worse · low certainty F

  • Some concerns about bias (RoB 2)
  • Few people (203 in all)
See the 1 study
  1. Temelimab versus placebo in patients with post-COVID condition. (2026)

    People in the study
    203 randomised
    Dose
    54 mg/kg, once monthly / every 4 weeks for 6 IV infusions over 24 weeks
    Outcome
    GAD-7 generalized anxiety disorder (GAD 7)
    Effect
    worse
    Risk of bias
    RoB 2: Some concerns
    Randomisation process
    Low
    Deviations from intended interventions
    Low
    Missing outcome data
    Low
    Measurement of the outcome
    Low
    Selection of the reported result
    Some concerns
Depression1 study · 96 people received temelimab Worse F
Low certainty

Why this grade: Worse, low certainty, from randomised trials: some concerns about bias (RoB 2); few people (203 in all).

The placebo trial203 randomised · Week 24 · 54 mg/kg, once monthly / every 4 weeks for 6 IV infusions over 24 weeks

Depression was worse with temelimab.

Temelimab may worsen depression in long COVID. Worse · low certainty F

  • Some concerns about bias (RoB 2)
  • Few people (203 in all)
See the 1 study
  1. Temelimab versus placebo in patients with post-COVID condition. (2026)

    People in the study
    203 randomised
    Dose
    54 mg/kg, once monthly / every 4 weeks for 6 IV infusions over 24 weeks
    Outcome
    PHQ-9 patient health questionnaire (PHQ-9)
    Effect
    worse
    Risk of bias
    RoB 2: Some concerns
    Randomisation process
    Low
    Deviations from intended interventions
    Low
    Missing outcome data
    Low
    Measurement of the outcome
    Low
    Selection of the reported result
    Some concerns

Daily life and health overall

Daily functioning1 study · 96 people received temelimab Little or no difference D
Very low certainty

Why this grade: Little or no difference, very low certainty, from randomised trials: some concerns about bias (RoB 2); one trial of 203 people found no clear difference; a small benefit can't be ruled out.

The placebo trial203 randomised · Week 24 · 54 mg/kg, once monthly / every 4 weeks for 6 IV infusions over 24 weeks

No clear difference in daily functioning.

The evidence is very uncertain about the effect of temelimab on daily functioning in long COVID. Little or no difference · very low certainty D

  • Some concerns about bias (RoB 2)
  • One trial of 203 people found no clear difference; a small benefit can't be ruled out
See the 1 study
  1. Temelimab versus placebo in patients with post-COVID condition. (2026)

    People in the study
    203 randomised
    Dose
    54 mg/kg, once monthly / every 4 weeks for 6 IV infusions over 24 weeks
    Outcome
    Sheehan Disability Scale [SDS] SDS
    Effect
    no clear difference
    Risk of bias
    RoB 2: Some concerns
    Randomisation process
    Low
    Deviations from intended interventions
    Low
    Missing outcome data
    Low
    Measurement of the outcome
    Low
    Selection of the reported result
    Some concerns
Overall symptoms1 study · 96 people received temelimab Little or no difference D
Very low certainty

Why this grade: Little or no difference, very low certainty, from randomised trials: some concerns about bias (RoB 2); one trial of 203 people found no clear difference; a small benefit can't be ruled out.

The placebo trial203 randomised · Week 24 · 54 mg/kg, once monthly / every 4 weeks for 6 IV infusions over 24 weeks

No clear difference in overall symptoms.

The evidence is very uncertain about the effect of temelimab on overall symptoms in long COVID. Little or no difference · very low certainty D

  • Some concerns about bias (RoB 2)
  • One trial of 203 people found no clear difference; a small benefit can't be ruled out
See the 1 study
  1. Temelimab versus placebo in patients with post-COVID condition. (2026)

    People in the study
    203 randomised
    Dose
    54 mg/kg, once monthly / every 4 weeks for 6 IV infusions over 24 weeks
    Outcome
    secondary outcomes overall
    Effect
    no clear difference
    Risk of bias
    RoB 2: Some concerns
    Randomisation process
    Low
    Deviations from intended interventions
    Low
    Missing outcome data
    Low
    Measurement of the outcome
    Low
    Selection of the reported result
    Some concerns
Quality of life1 study · 96 people received temelimab Worse F
Low certainty

Why this grade: Worse, low certainty, from randomised trials: some concerns about bias (RoB 2); few people (203 in all).

The placebo trial203 randomised · Week 24 · 54 mg/kg, once monthly / every 4 weeks for 6 IV infusions over 24 weeks

Quality of life was worse with temelimab.

Temelimab may worsen quality of life in long COVID. Worse · low certainty F

  • Some concerns about bias (RoB 2)
  • Few people (203 in all)
See the 1 study
  1. Temelimab versus placebo in patients with post-COVID condition. (2026)

    People in the study
    203 randomised
    Dose
    54 mg/kg, once monthly / every 4 weeks for 6 IV infusions over 24 weeks
    Outcome
    EQ5D-5L European quality of life 5-dimension-5-level (EQ5D-5L) scale
    Effect
    worse
    Risk of bias
    RoB 2: Some concerns
    Randomisation process
    Low
    Deviations from intended interventions
    Low
    Missing outcome data
    Low
    Measurement of the outcome
    Low
    Selection of the reported result
    Some concerns

Side effects

No study of this treatment alone reported side effects we could read.

Doses studied

What researchers used, as the papers print it; not a recommendation.

  1. 1Start

    54 mg at the start

  2. 2Top dose

    Most often 54 mg (1 of 1 studies)

Doses across 1 study

54 to 54 mg.

Each study’s dose, as printed

All papers

  1. Temelimab versus placebo in patients with post-COVID condition.2026 · placebo trial · 203 randomised
    Summary

    This randomized, double-blind, placebo-controlled, multicenter phase II trial enrolled 203 adults with post-COVID condition and positive HERV-W ENV at 14 centres in Switzerland, Italy, and Spain; 72% were women and mean age was 46 (SD 10). Participants received 54 mg/kg Temelimab or matching placebo intravenously once monthly for six infusions over 24 weeks, with current standard of care. The primary endpoint was a decrease of at least 3 points on the PROMIS Fatigue SF 7a scale from baseline to Week 24. At Week 24, a decrease of at least 3 points occurred in 47 of 96 Temelimab participants and 51 of 94 placebo participants. Mean PROMIS decrease was 3.2 points with Temelimab and 3.8 with placebo; the between-group difference was 0.62 (95% CI -0.78 to 2.01), and the relative risk was 0.9 (95% CI 0.6–1.2). Secondary outcomes also did not show differences between groups. No significant adverse events were reported, and there was no difference in adverse effects reported between groups. The authors state limitations including lack of an objective measurement in the primary outcome and power only for the primary outcome.

A little hope, every Sunday

New recovery stories and data-driven research on ME/CFS and long COVID. Ideas worth considering, and the evidence behind them.

Free · Unsubscribe anytime